Opioid agonist treatment and the process of injection drug use initiation

被引:27
|
作者
Luisa Mittal, Maria [1 ,2 ]
Jain, Sonia [3 ]
Sun, Shelly [3 ]
DeBeck, Kora [4 ]
Milloy, M. J. [4 ]
Hayashi, Kanna [4 ,5 ]
Hadland, Scott E. [6 ,7 ,8 ]
Werb, Dan [1 ]
机构
[1] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92093 USA
[2] Univ Xochicalco, Sch Med, Tijuana, Mexico
[3] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA
[4] St Pauls Hosp, BC Ctr Subst Use, Vancouver, BC, Canada
[5] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada
[6] Boston Univ, Sch Med, Dept Pediat, Div Gen Pediat, Boston, MA 02118 USA
[7] Boston Med Ctr, Dept Pediat, Boston, MA USA
[8] Boston Med Ctr, Grayken Ctr Addict, Boston, MA USA
关键词
Opioid agonist treatment; Overdose prevention; HIV prevention; HCV prevention; Persons who inject drugs; Methadone; Suboxone; Treatment as prevention; C VIRUS-INFECTION; USE DISORDERS; METHADONE; VANCOUVER; PEOPLE; HIV; TRANSMISSION; DEPENDENCE; PATTERNS; CONTEXT;
D O I
10.1016/j.drugalcdep.2018.12.018
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background Opioid agonist treatment (OAT) is an effective biomedical intervention to manage opioid use disorder among persons who inject drugs (PWID). Preliminary evidence suggests that OAT may also disrupt the social communicability of injection drug use (IDU) practices by established PWID. We therefore aim to investigate the association between OAT enrollment and initiating others into IDU among PWID in Vancouver, Canada. Methods: Preventing Injecting by Modifying Existing Responses (PRIMER; NIDA DP2-DA040256-01) is a prospective multi-cohort study seeking to identify structural interventions that reduce the risk that PWID initiate others into IDU. The present analysis was conducted using data from a participating cohort of PWID in Vancouver, Canada, between December 2014 and May 2017. Multivariable logistic regression models were built to assess the association between reporting active (i.e., within the past six months) OAT enrollment and assisting others in injection initiation. A final model was determined using a manual stepwise approach whereby covariates were excluded if their removal altered the coefficient of interest by < 5%. Results: Participants (n = 1740) were predominantly male (62.3%); 35.1% reported daily injecting (n = 611); 860 (49.4%) reported active OAT enrollment, and 80 (4.6%) reported recently providing injection initiation assistance. In a multivariable model, participants who reported active OAT enrollment had significantly lower odds of recently providing injection initiation assistance (Adjusted Odds Ratio = 0.52, 95% Confidence Interval: 0.31-0.87, P = 0.01). Conclusion: Results suggest a protective association between OAT and the expansion of IDU practices among vulnerable populations, suggesting its potential use as 'addiction treatment as prevention.'
引用
收藏
页码:354 / 360
页数:7
相关论文
共 50 条
  • [31] Predictors of timely opioid agonist treatment initiation among veterans with and without HIV
    Wyse, Jessica J.
    Robbins, Jonathan L.
    McGinnis, Kathleen A.
    Edelman, E. Jennifer
    Gordon, Adam J.
    Manhapra, Ajay
    Fiellin, David A.
    Moore, Brent A.
    Korthuis, P. Todd
    Gaither, Julie R.
    Gordon, Kirsha
    Skanderson, Melissa
    Barry, Declan T.
    Crystal, Stephen
    Justice, Amy
    Kraemer, Kevin L.
    DRUG AND ALCOHOL DEPENDENCE, 2019, 198 : 70 - 75
  • [32] Short-Acting, Full Agonist Opioids During Initiation of Opioid Agonist Treatment in the Fentanyl Era
    Saxon, Andrew J.
    JAMA NETWORK OPEN, 2024, 7 (05)
  • [33] Pay for Performance and Treatment Outcome in Agonist Treatment for Opioid Use Disorder
    Loscalzo, Emily
    Levit, Alexander
    Sterling, Robert C.
    Weinstein, Stephen P.
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (02): : 173 - 178
  • [34] Opioid Agonist Maintenance for Probationers: Patient-Level Predictors of Treatment Retention, Drug Use, and Crime
    Gryczynski, Jan
    Kinlock, Timothy W.
    Kelly, Sharon M.
    O'Grady, Kevin E.
    Gordon, Michael S.
    Schwartz, Robert P.
    SUBSTANCE ABUSE, 2012, 33 (01) : 30 - 39
  • [35] Exploring Patients' Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice
    Friedmann, Zoe
    Binder, Annette
    Kinkel, Hans-Tilmann
    Kuehner, Claudia
    Zsolnai, Andreas
    Mick, Inge
    EUROPEAN ADDICTION RESEARCH, 2024, 30 (01) : 32 - 42
  • [36] Initiation of opioid agonist treatment and subsequent substance use and other patterns among adolescents and young adults in Vancouver, Canada
    Pilarinos, Andreas
    Fast, Danya
    Nosova, Ekaterina
    Kwa, Yandi
    Joe, Ronald
    Buxton, Jane A.
    DeBeck, Kora
    DRUG AND ALCOHOL DEPENDENCE, 2022, 235
  • [37] Changes in Opioid Agonist Treatment Initiation Following Voluntary and Mandatory Prescription Drug Monitoring Program Implementation: A Time Series Analysis
    Picco, Louisa
    Xia, Ting
    Bell, Simon
    Lubman, Dan
    Buchbinder, Rachelle
    Nielsen, Suzanne
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [38] Ethical Considerations in Use of Injectable Opioid Agonist Treatment in Pregnancy
    Weaver, Michael
    JOURNAL OF ADDICTION MEDICINE, 2021, 15 (05) : 357 - 358
  • [39] Childhood sexual abuse and age at initiation of injection drug use
    Ompad, DC
    Ikeda, RM
    Shah, N
    Fuller, CM
    Bailey, S
    Morse, E
    Kerndt, P
    Maslow, C
    Wu, YF
    Vlahov, D
    Garfein, R
    Strathdee, SA
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2005, 95 (04) : 703 - 709
  • [40] Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder
    Ellis, Matthew S.
    Buttram, Mance E.
    Kasper, Zachary A.
    DRUG AND ALCOHOL DEPENDENCE, 2022, 234